A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial

Srdan Verstovsek; Moshe Talpaz; Martha Wadleigh; Alessandro Isidori; Peter Te Boekhorst; Michael R Savona; Prithviraj Bose; Olga Pozdnyakova; Ruben Mesa; Tarec C El-Galaly; Jennifer O'Sullivan; Katia Gamel; Brian Higgins; Sudhakar Katakam; Boyan Todorov; Kerstin Trunzer; Claire N Harrison

doi:10.3324/haematol.2023.284410

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial

Haematologica. 2024 Jun 1;109(6):1977-1983. doi: 10.3324/haematol.2023.284410.

Authors

Srdan Verstovsek¹, Moshe Talpaz², Martha Wadleigh³, Alessandro Isidori⁴, Peter Te Boekhorst⁵, Michael R Savona⁶, Prithviraj Bose¹, Olga Pozdnyakova⁷, Ruben Mesa⁸, Tarec C El-Galaly⁹, Jennifer O'Sullivan¹⁰, Katia Gamel¹¹, Brian Higgins¹², Sudhakar Katakam¹¹, Boyan Todorov¹¹, Kerstin Trunzer¹¹, Claire N Harrison¹³

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX.
² Michigan Medicine - The University of Michigan, Ann Arbor, MI.
³ Dana-Farber Cancer Institute, Boston, MA.
⁴ Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy.
⁵ Erasmus Medical Center, Rotterdam, the Netherlands.
⁶ Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.
⁷ Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
⁸ Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC.
⁹ Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.
¹⁰ Guy's and St Thomas' NHS Foundation Trust, London.
¹¹ F. Hoffmann-La Roche, Ltd., Basel.
¹² Genentech Inc, South San Francisco, CA.
¹³ Guy's and St Thomas' NHS Foundation Trust, London. claire.harrison@gstt.nhs.uk.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Double-Blind Method
Female
Humans
Male
Middle Aged
Nitriles* / therapeutic use
Primary Myelofibrosis* / drug therapy
Pyrazoles* / therapeutic use
Pyrimidines* / therapeutic use
Treatment Outcome

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib

Grants and funding

Funding: This study was supported by Promedior (original sponsor) and F. Hoffmann-La Roche, Ltd. (current sponsor). Medical writing support, under the direction of the authors, was provided by Fiona Scott, PhD, on behalf of CMC Affinity, a division of IPG Health Medical Communications, funded by F. Hoffmann-La Roche, Ltd, in accordance with Good Publication Practice (GPP 2022) guidelines.